Abstract:Background: Digital health technologies (DHTs) play an ever-expanding role in health care management and delivery. Beyond their use as interventions, DHTs also serve as a vehicle for real-world data collection to characterize patients, their care journeys, and their responses to other clinical interventions. There is a need to comprehensively map the evidence-across all conditions and technology types-on DHT measurement of patient outcomes in the real world. Objective: We aimed to investigate the use of DHTs to measure real-world clinical outcomes using patient-generated data. Methods: We conducted this systematic scoping review in accordance with the Joanna Briggs Institute methodology. Detailed eligibility criteria documented in a preregistered protocol informed a search strategy for the following databases: MEDLINE (Ovid), CINAHL, Cochrane (CENTRAL), Embase, PsycINFO, ClinicalTrials.gov, and the EU Clinical Trials Register. We considered studies published between 2000 and 2022 wherein digital health data were collected, passively or actively, from patients with any specified health condition outside of clinical visits. Categories for key concepts, such as DHT type and analytical applications, were established where needed. Following screening and full-text review, data were extracted and analyzed using predefined fields, and findings were reported in accordance with established guidelines. Results: The search strategy identified 11,015 publications, with 7308 records after duplicates and reviews were removed. After screening and full-text review, 510 studies were included for extraction. These studies encompassed 169 different conditions in over 20 therapeutic areas and 44 countries. The DHTs used for mental health and addictions research (111/510, 21.8%) were the most prevalent. The most common type of DHT, mobile apps, was observed in approximately half of the studies (250/510, 49%). Most studies used only 1 DHT (346/510, 67.8%); however, the majority of technologies used were able to collect more than 1 type of data, with the most common being physiological data (189/510, 37.1%), clinical symptoms data (188/510, 36.9%), and behavioral data (171/510, 33.5%). Overall, there has been real growth in the depth and breadth of evidence, number of DHT types, and use of artificial intelligence and advanced analytics over time. Conclusions: This scoping review offers a comprehensive view of the variety of types of technology, data, collection methods, analytical approaches, and therapeutic applications within this growing body of evidence. To unlock the full potential of DHT for measuring health outcomes and capturing digital biomarkers, there is a need for more rigorous research that goes beyond technology validation to demonstrate whether robust real-world data can be reliably captured from patients in their daily life and whether its capture improves patient outcomes. This study provides a valuable repository of DHT studies to inform subsequent research by health care providers, policy makers, and the life sciences industry. Trial registration: Open Science Framework 5TMKY; https://osf.io/5tmky/.

Fatal hemophagocytic lymphohistiocytosis in X‐linked chronic granulomatous disease associated with a perforin gene variant

Quantifying the Benefits of Digital Biomarkers and Technology-Based Study Endpoints in Clinical Trials: Project Moneyball

Digitizing clinical trials

Tepid Uptake of Digital Health Technologies in Clinical Trials by Pharmaceutical and Medical Device Firms

The long-term clinical impact of digital endpoints and biomarkers in data collection

Digital endpoints in clinical trials: emerging themes from a multi-stakeholder Knowledge Exchange event

Ant colony optimization based polymorphism-aware routing algorithm for ad hoc UAV network

Digital health technology in clinical trials

Clinical Evaluation of Digital Therapeutics: Present and Future

Electrospun Biomimic Nanofibrous Scaffolds of Silk Fibroin/Hyaluronic Acid for Tissue Engineering

Remote Digital Monitoring for Medical Product Development

Unlocking the full potential of digital endpoints for decision making: a novel modular evidence concept enabling re-use and advancing collaboration

Patient-centricity in digital measure development: co-evolution of best practice and regulatory guidance

Digital Tools-Regulatory Considerations for Application in Clinical Trials

Unleashing the full potential of digital outcome measures in clinical trials: eight questions that need attention

Digital health technology derived measures: Biomarkers or clinical outcome assessments?

Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016

Digital Health Technology for Real-World Clinical Outcome Measurement Using Patient-Generated Data: Systematic Scoping Review

Empowering drug development: Leveraging insights from imaging technologies to enable the advancement of digital health technologies

Reverse Engineering of Digital Measures: Inviting Patients to the Conversation

Tracing Digital Therapeutics Research Across Medical Specialties: Evidence from ClinicalTrials.gov